![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: USP7 |
Gene summary for USP7 |
![]() |
Gene information | Species | Human | Gene symbol | USP7 | Gene ID | 7874 |
Gene name | ubiquitin specific peptidase 7 | |
Gene Alias | HAFOUS | |
Cytomap | 16p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000723 | UniProtAcc | B7ZAX6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7874 | USP7 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.86e-06 | 4.64e-01 | -0.1954 |
7874 | USP7 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.08e-02 | 5.37e-01 | 0.281 |
7874 | USP7 | A002-C-010 | Human | Colorectum | FAP | 3.22e-03 | -1.50e-01 | 0.242 |
7874 | USP7 | A001-C-207 | Human | Colorectum | FAP | 3.18e-02 | -1.97e-01 | 0.1278 |
7874 | USP7 | A015-C-203 | Human | Colorectum | FAP | 6.88e-21 | -1.84e-01 | -0.1294 |
7874 | USP7 | A015-C-204 | Human | Colorectum | FAP | 1.22e-03 | -6.90e-02 | -0.0228 |
7874 | USP7 | A002-C-201 | Human | Colorectum | FAP | 1.48e-07 | -1.24e-01 | 0.0324 |
7874 | USP7 | A002-C-203 | Human | Colorectum | FAP | 1.60e-03 | -6.90e-02 | 0.2786 |
7874 | USP7 | A001-C-108 | Human | Colorectum | FAP | 7.29e-12 | -8.90e-02 | -0.0272 |
7874 | USP7 | A002-C-205 | Human | Colorectum | FAP | 9.49e-15 | -1.65e-01 | -0.1236 |
7874 | USP7 | A015-C-006 | Human | Colorectum | FAP | 1.13e-08 | -2.99e-01 | -0.0994 |
7874 | USP7 | A015-C-106 | Human | Colorectum | FAP | 1.87e-10 | -6.87e-02 | -0.0511 |
7874 | USP7 | A002-C-114 | Human | Colorectum | FAP | 2.40e-11 | -1.95e-01 | -0.1561 |
7874 | USP7 | A015-C-104 | Human | Colorectum | FAP | 2.00e-24 | 1.78e-02 | -0.1899 |
7874 | USP7 | A001-C-014 | Human | Colorectum | FAP | 3.17e-10 | -1.35e-01 | 0.0135 |
7874 | USP7 | A002-C-016 | Human | Colorectum | FAP | 3.35e-18 | -1.93e-01 | 0.0521 |
7874 | USP7 | A015-C-002 | Human | Colorectum | FAP | 7.67e-08 | -3.19e-01 | -0.0763 |
7874 | USP7 | A001-C-203 | Human | Colorectum | FAP | 1.66e-10 | -9.89e-02 | -0.0481 |
7874 | USP7 | A002-C-116 | Human | Colorectum | FAP | 1.94e-22 | -3.34e-01 | -0.0452 |
7874 | USP7 | A014-C-008 | Human | Colorectum | FAP | 1.12e-07 | -7.91e-02 | -0.191 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00355205 | Thyroid | PTC | monoubiquitinated protein deubiquitination | 8/5968 | 10/18723 | 2.46e-03 | 1.27e-02 | 8 |
GO:0045861113 | Thyroid | PTC | negative regulation of proteolysis | 136/5968 | 351/18723 | 3.54e-03 | 1.71e-02 | 136 |
GO:190179914 | Thyroid | PTC | negative regulation of proteasomal protein catabolic process | 25/5968 | 49/18723 | 4.09e-03 | 1.95e-02 | 25 |
GO:19036498 | Thyroid | PTC | regulation of cytoplasmic transport | 16/5968 | 28/18723 | 4.99e-03 | 2.31e-02 | 16 |
GO:00165794 | Thyroid | PTC | protein deubiquitination | 59/5968 | 139/18723 | 5.50e-03 | 2.50e-02 | 59 |
GO:00463644 | Thyroid | PTC | monosaccharide biosynthetic process | 37/5968 | 82/18723 | 8.07e-03 | 3.40e-02 | 37 |
GO:00162333 | Thyroid | PTC | telomere capping | 20/5968 | 39/18723 | 9.09e-03 | 3.76e-02 | 20 |
GO:00109066 | Thyroid | PTC | regulation of glucose metabolic process | 50/5968 | 119/18723 | 1.25e-02 | 4.88e-02 | 50 |
GO:001049832 | Thyroid | ATC | proteasomal protein catabolic process | 309/6293 | 490/18723 | 1.78e-41 | 1.13e-37 | 309 |
GO:0043161210 | Thyroid | ATC | proteasome-mediated ubiquitin-dependent protein catabolic process | 265/6293 | 412/18723 | 7.09e-38 | 1.49e-34 | 265 |
GO:004217635 | Thyroid | ATC | regulation of protein catabolic process | 239/6293 | 391/18723 | 2.63e-29 | 1.85e-26 | 239 |
GO:190336235 | Thyroid | ATC | regulation of cellular protein catabolic process | 168/6293 | 255/18723 | 3.50e-26 | 1.58e-23 | 168 |
GO:003238632 | Thyroid | ATC | regulation of intracellular transport | 203/6293 | 337/18723 | 6.16e-24 | 1.85e-21 | 203 |
GO:190305035 | Thyroid | ATC | regulation of proteolysis involved in cellular protein catabolic process | 146/6293 | 221/18723 | 4.18e-23 | 1.20e-20 | 146 |
GO:006113633 | Thyroid | ATC | regulation of proteasomal protein catabolic process | 128/6293 | 187/18723 | 1.63e-22 | 4.30e-20 | 128 |
GO:2000058210 | Thyroid | ATC | regulation of ubiquitin-dependent protein catabolic process | 116/6293 | 164/18723 | 2.15e-22 | 5.43e-20 | 116 |
GO:0032434210 | Thyroid | ATC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 100/6293 | 134/18723 | 2.41e-22 | 5.86e-20 | 100 |
GO:003164734 | Thyroid | ATC | regulation of protein stability | 177/6293 | 298/18723 | 4.08e-20 | 6.46e-18 | 177 |
GO:001657017 | Thyroid | ATC | histone modification | 243/6293 | 463/18723 | 2.23e-17 | 2.27e-15 | 243 |
GO:003304423 | Thyroid | ATC | regulation of chromosome organization | 119/6293 | 187/18723 | 3.55e-17 | 3.40e-15 | 119 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05169 | Colorectum | MSS | Epstein-Barr virus infection | 63/1875 | 202/8465 | 1.63e-03 | 8.98e-03 | 5.50e-03 | 63 |
hsa051691 | Colorectum | MSS | Epstein-Barr virus infection | 63/1875 | 202/8465 | 1.63e-03 | 8.98e-03 | 5.50e-03 | 63 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa040689 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa0406814 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0516921 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa040684 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
hsa0516931 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa040685 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa052033 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
hsa0516928 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa052038 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
hsa040688 | Oral cavity | OSCC | FoxO signaling pathway | 85/3704 | 131/8465 | 7.50e-07 | 4.33e-06 | 2.21e-06 | 85 |
hsa05169113 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa0520314 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
hsa0406813 | Oral cavity | OSCC | FoxO signaling pathway | 85/3704 | 131/8465 | 7.50e-07 | 4.33e-06 | 2.21e-06 | 85 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP7 | SNV | Missense_Mutation | novel | c.2788N>C | p.Glu930Gln | p.E930Q | Q93009 | protein_coding | tolerated(0.24) | benign(0.022) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
USP7 | SNV | Missense_Mutation | novel | c.598N>G | p.Pro200Ala | p.P200A | Q93009 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
USP7 | SNV | Missense_Mutation | c.2941N>C | p.Asp981His | p.D981H | Q93009 | protein_coding | tolerated(0.12) | benign(0.001) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
USP7 | SNV | Missense_Mutation | c.1223N>A | p.Arg408Lys | p.R408K | Q93009 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
USP7 | SNV | Missense_Mutation | novel | c.913G>A | p.Asp305Asn | p.D305N | Q93009 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP7 | SNV | Missense_Mutation | c.2317N>T | p.Pro773Ser | p.P773S | Q93009 | protein_coding | tolerated(0.72) | benign(0.036) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
USP7 | SNV | Missense_Mutation | c.3011G>A | p.Gly1004Glu | p.G1004E | Q93009 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
USP7 | SNV | Missense_Mutation | novel | c.556N>A | p.Asp186Asn | p.D186N | Q93009 | protein_coding | tolerated(0.41) | benign(0.1) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
USP7 | insertion | Nonsense_Mutation | novel | c.464_465insGTTTTCAATCTAAGT | p.Ser155delinsArgPheSerIleTerVal | p.S155delinsRFSI*V | Q93009 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
USP7 | deletion | Frame_Shift_Del | novel | c.1939delA | p.Thr647GlnfsTer2 | p.T647Qfs*2 | Q93009 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7874 | USP7 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME, PROTEASE | PMID26077642-Compound-Vif1 | |||
7874 | USP7 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME, PROTEASE | PMID26077642-Compound-Vif2 |
Page: 1 |